Brief: Abbott -Deal Expected To Be Dilutive To Adjusted Earnings Per Share Through 2027- SEC Filing
20/11/2025 13:13
Abbott Laboratories ABT.N: ABBOTT -DEAL EXPECTED TO BE DILUTIVE TO ADJUSTED EARNINGS PER SHARE THROUGH 2027- SEC FILING ABBOTT: EXACT SCIENCES TO PAY OR CAUSE TO BE PAID BY A U.S. PERSON TO ABBOTT $628.7 MILLION IF DEAL IS TERMINATED UNDER SOME CIRCUMSTANCES - SEC FILING Source text: [ID:n0001104659-25-114422] Further company coverage: ABT.N
Recent news on Abbott Laboratories
See all newsBrief: FDA Approves Abbott HIV Combo Next Assay
Press Digest: Wall Street Journal - June 29
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports (updated)
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
Factbox: Major deals involving US drugmakers and biotechs over the past decade